Comparative evaluation of disc diffusion and Liofilchem™ MTS strip methods with broth microdilution for cefepime/enmetazobactam susceptibility testing
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf051 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Cécile Emeraud und 7 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases » (IMVA-HB/IDMIT/UMRS1184), T…. Hauptthemen laut MEDLINE: Cefepime, Anti-Bacterial Agents, Disk Diffusion Antimicrobial Tests, Enterobacteriaceae. Die Arbeit nennt 10 Literaturangaben. Gefördert von: French National Reference Center for Antimicrobial Resistance.
Abstract (Originalsprache)
Background
Cefepime/enmetazobactam is a newly approved β-lactam/β-lactamase inhibitor combination with promising activity against MDR Gram-negative Enterobacterales, particularly ESBL- and OXA-48-producing isolates. Reliable susceptibility testing methods are essential to guide its clinical use.
Objectives
To evaluate the performance of two commercial cefepime/enmetazobactam susceptibility testing methods, disc diffusion and Liofilchem™ MTS gradient strips, using broth microdilution (BMD) as the gold standard.
Methods
A total of 291 carbapenem-resistant Enterobacterales isolates, including 194 carbapenemase producers, were included. Susceptibility testing was performed using BMD, disc diffusion and Liofilchem™ MTS strips. Results were interpreted following EUCAST and FDA 2025 breakpoints. Essential agreement (EA) and bias were calculated for gradient strip methods according to the ISO 20776-2021 guideline, whereas categorical agreement (CA), very major errors (VMEs) and major errors (MEs) were determined for disc diffusion according to the ISO 20776-2:2007 guideline.
Results
The disc diffusion method demonstrated high CA (93.8% EUCAST, 95.9% FDA). VME rates exceeded acceptable thresholds using EUCAST breakpoints (20.8%) but were within limits for FDA (1.9%). Liofilchem™ MTS strips achieved 88.3% (95% CI: 84.1%–91.5%) EA and a bias of −8.9%. Both methods accurately detected susceptibility in OXA-48-producing isolates but showed limitations for isolates close to the MIC breakpoints.
Conclusions
Disc diffusion and Liofilchem™ MTS strips represent reliable alternatives to BMD for routine cefepime/enmetazobactam testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases » (IMVA-HB/IDMIT/UMRS1184), Team Resist, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
- Bacteriology-Hygiene Unit, Bicêtre Hospital Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
- Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacterales, Le Kremlin-Bicêtre, France.
ORCID-Profile: Laurent Dortet
Förderung
- French National Reference Center for Antimicrobial Resistance
Zitieren
APA
Emeraud, C., De Swardt, H., Bernabeu, S., Latour, L., Pages, A., Ronsin, S., Bonnin, R. A., & Dortet, L. (2025). Comparative evaluation of disc diffusion and Liofilchem™ MTS strip methods with broth microdilution for cefepime/enmetazobactam susceptibility testing. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf051
Vancouver
Emeraud C, De Swardt H, Bernabeu S, Latour L, Pages A, Ronsin S, et al. Comparative evaluation of disc diffusion and Liofilchem™ MTS strip methods with broth microdilution for cefepime/enmetazobactam susceptibility testing. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf051
BibTeX
@article{Emeraud2025,
author = {Emeraud, Cécile and De Swardt, Hippolyte and Bernabeu, Sandrine and Latour, Lena and Pages, Alice and Ronsin, Sarah and Bonnin, Rémy A and Dortet, Laurent},
title = {Comparative evaluation of disc diffusion and Liofilchem™ MTS strip methods with broth microdilution for cefepime/enmetazobactam susceptibility testing},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf051}
}
EUVIMED